- Date 15 October 2014
- Documents : 5
- Economic analysis
- History
Listen
ZOSTAVAX, live attenuated shingles (herpes zoster) vaccine
INFECTIOLOGY - New medicinal product
Opinions on drugs -
Posted on
Feb 23 2015
Reason for request
Inclusion
Minor therapeutic improvement in the prevention of herpes zoster and postherpetic neuralgia in the populations recommended by the French High Council for Public Health
- ZOSTAVAX is a live attenuated vaccine with Marketing Authorisation in the prevention of herpes zoster and postherpetic neuralgia in adults age 50 and over.
- Its efficacy is modest on the incidence of herpes zoster and its protection decreases with the vaccination age and over time.
- This vaccine must be used according to the recommendations of the French High Council for Public Health (HCSP), i.e. in non-immunocompromised patients 65 to 74 years old.
Clinical Benefit
| Moderate |
In view of:
the Committee considers that the actual benefit of ZOSTAVAX is moderate in the prevention of zoster and post-herpetic neuralgia, in the populations recommended by the HCSP. |
Clinical Added Value
| minor |
ZOSTAVAX provides a minor clinical added value, level IV) in the prevention of herpes zoster, in the populations recommended by the HCSP. |
-
